ETON Stock Forecast & Price Target

Eton Pharmaceuticals is well positioned fundamentally because its rare-disease portfolio is now being driven by HEMANGEOL’s rapid channel conversion, with about 95% of the roughly 8,000 inherited patients moved into the Eton Cares model and annualized revenue implied at roughly $64M-$80M from the current base. The company delivered record 2Q26 revenue of $37.6M, up 99% YoY and 55% QoQ, while net income reached $0.35 per diluted share and FY26 revenue guidance was raised to at least $145M, suggesting meaningful operating leverage as the product mix scales. Its outlook is further strengthened by a cash balance of $26.8M, expected positive cash flow, and a steady bolt-on strategy that adds de-risked late-stage assets and expands future growth optionality within an already owned rare-disease commercial infrastructure.

Eton Pharmaceuticals is viewed negatively because it has a history of operating losses, and while it posted positive GAAP net income for the first time in 3Q24, there is no assurance that profitability can be sustained. The company’s valuation also depends on adoption of its commercial assets, but slower-than-expected uptake could materially weaken results. In addition, Eton remains a small company with limited resources that has relied on PIPEs, public offerings, and expanded credit facilities, and may need more capital again if it cannot sustain positive cash flow.